Collegium Pharmaceutical (COLL) - חוב לטווח ארוך להון

The following Collegium Pharmaceutical (COLL) quotes demonstrate the impact of fierce competition in the pain management niche and pressure from peers, with the indicator standing at 3.46. The business relies on the modernization of packaging lines to minimize disruptions. Revenue stability is ensured by the implementation of unique drug abuse-deterrent systems, transforming the medication lineup into a reliable cash cow.

The large-scale implementation of automated filling lines and supply control systems for prescription drugs requires significant capital expenditures in the infrastructure of Collegium Pharmaceutical (COLL). Analyzing the current long-term debt-to-equity ratio, an investor sees the proportion of liabilities with a maturity of over one year to net assets, which allows for an assessment of the degree of financial autonomy and the stability of the balance sheet structure during business expansion.